We welcome your views on our website and invite you to take part in a brief survey when you've finished your visit.
Your response will help us improve the site and the experience we offer to visitors.
Some of the principal treatments carried out by Dr Naveed Sarwar at Spire include:
I have been a Consultant Medical Oncologist for eight years in a London Cancer Centre and am an expert in the management of Urological and Breast Cancers specialising in the delivery of chemotherapy, immunotherapy, endocrine therapy and targeted therapies. I specialise in Medical Oncology with a special interest in the management of Genito-urinary cancers (prostate, kidney, testes and bladder), Breast cancer and Gynaecological Malignancies.
Any patient I see will receive a careful and thorough assessment of their cancer and related medical conditions. They can expect a comprehensive discussion of all treatment options in lay terms and to be guided to the optimum management plan catering to their specific needs. When needed, chemotherapy and hormone treatment take place at Spire Hartswood Hospital, Brentwood, or Spire Wellesley Hospital, Southend. For patients needing radiotherapy, I will arrange this via a clinical oncology colleague.
I am actively involved in clinical trial research into urological cancer, and a member of the London Kidney Cancer Group, which aims to develop further clinical trials in the London area. I specialise in the management of prostate, kidney, testes and bladder cancers. I am a lead oncologist for the treatment of renal and testicular cancer in Essex and have been published in a number of peer reviewed journals. I am also lead medical oncologist and leas for clinical research for gynaecological cancers in Essex. My research interests include the molecular mechanisms that determine sensitivity and resistance to endocrine therapy in breast cancer, as well as clinical trials of new biological agents for breast cancer. I specialise in the treatment of breast cancer using a combination of chemotherapy and hormonal therapies.
My main research interests include the molecular mechanisms that determine sensitivity and resistance to endocrine therapy in breast cancer, as well as clinical trials of novel agents for breast cancer and urological cancers.
I am a member of the National Testicular Cancer Clinical Study group and am Research and Clinical Lead for Urological Cancers at Imperial College Healthcare NHS Trust.
I am actively involved in the training of junior doctors and am a member on the Medical Oncology Specialist Training Committee for the London Deanery.
I qualified as a doctor at St George's Hospital Medical School in London. I undertook my oncology training at the Charing Cross, Hammersmith, Chelsea and Westminster, Mount Vernon and The Royal Marsden hospitals. Between 2000 and 2004 I was a Clinical Research Fellow for Cancer Research UK. I completed my PhD in the investigation of resistance to endocrine therapies in breast cancer at Imperial College London. I have published on this and a number of other aspects of oncology. Consultations can be arranged to suit patients' availability.
Urological cancers: testis, Breast disease.
MRCP / Royal College of Physicians London / 2000
Membership of the Royal Colleges of Physicians
BSc in Immunology and Oncology / St George's Hospital Medical School / 1993
Bachelor of Science
MBBS / St George's Hospital Medical School / 1996
Bachelor of Medicine, Bachelor of Surgery
PhD / Imperial College London / 2006
Doctorate of Philosophy
Royal College of Physicians
European Society of Medical Oncology
British Medical Association
Research lead for Urological Malignancies for Imperial College Healthcare NHS Trust
Urology Sub-specialty research lead for North West London
Imperial College Healthcare NHS TrustBack to top
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer.
Carboplatin AUC 10 for IGCCCG good prognosis metastatic seminoma
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
A retrospective study to evaluate single agent methotrexate treatment in low risk gestational choriocarcinoma in the United Kingdom
I am married to Jina and have three lovely children. I am a keen sportsman and enjoy playing football, cricket and tennis and have played in a number of charity cricket matches to raise money for cancer charities. I enjoy spending time playing golf with my two sons.Back to top
|Telephone||Spire Hartswood 01277 266 766|
|Private secretary telephone||07787 407 424|
|Private secretary fax||0208 946 7188|
|Private secretary email@example.com|
11 February 2020
Redbridge-based Spire London East Hospital has been upgraded to a ‘Good’ rating following an inspection by the Care Qual…
04 February 2020
The Paterson Independent Inquiry published its final report on 4 February 2020.